We are grateful to all the researchers and scientists worldwide who have used our products. It is extremely rewarding for us to know that our products work for you. The following are some publications in which Selleck products have been used.
Jones DR, et al. PtdIns5P is an oxidative stress-induced second messenger that regulates PKB activation. FASEB J, 2012, ahead of print.
Polzer H, et al. CBL mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases. Exp Hematol, 2013, 41(3):271-280.e4.
McGuane JT, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology, 2011, 152(7):2786-96.
Petrich AM, et al. Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma. Clin Cancer Res, 2012, 18(9):2534-44.
Wang ZL, et al. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis, 2013, 34(3):638-46.
Santo EE, et al. FOXO3a Is A Major Target Of Inactivation By PI3K/AKT Signaling In Aggressive Neuroblastoma. Cancer Res, 2013, ahead of print.
Stegeman H, et al. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer, 2012, 12, 463.
Pauloin A, et al. Prolactin and epidermal growth factor stimulate adipophilin synthesis in HC11 mouse mammary epithelial cells via the PI3-kinase/Akt/mTOR pathway. Biochim Biophys Acta, 2012, 1823(5):987-96.
Sharma N, et al. Preventing the calorie restriction-induced increase in insulin-stimulated Akt2 phosphorylation eliminates calorie restriction's effect on glucose uptake in skeletal muscle. Biochim Biophys Acta, 2012, 1822(11):1735-40.
Hofmann I, et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One, 2012, 7(8):e44146.